105 related articles for article (PubMed ID: 21908039)
1. Dalcetrapib: turning the tide for CETP inhibition?
Stroes ES; van Wijk DF
Lancet; 2011 Oct; 378(9802):1529-30. PubMed ID: 21908039
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Fayad ZA; Mani V; Woodward M; Kallend D; Abt M; Burgess T; Fuster V; Ballantyne CM; Stein EA; Tardif JC; Rudd JH; Farkouh ME; Tawakol A;
Lancet; 2011 Oct; 378(9802):1547-59. PubMed ID: 21908036
[TBL] [Abstract][Full Text] [Related]
3. Dalcetrapib , a cholesteryl ester transfer protein modulator.
Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2012 Sep; 21(9):1427-32. PubMed ID: 22725099
[TBL] [Abstract][Full Text] [Related]
4. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
[TBL] [Abstract][Full Text] [Related]
5. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
[TBL] [Abstract][Full Text] [Related]
7. Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein.
Pitts R; Gunzburger E; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Nicholls SJ; Niesor EJ; Olsson AG; Shah PK; Tardif JC; Kittelson J; Schwartz GG
J Am Coll Cardiol; 2016 Dec; 68(22):2488-2490. PubMed ID: 27908356
[No Abstract] [Full Text] [Related]
8. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
Ray KK; Ditmarsch M; Kallend D; Niesor EJ; Suchankova G; Upmanyu R; Anzures-Cabrera J; Lehnert V; Pauly-Evers M; Holme I; Štásek J; van Hessen MW; Jones P;
Eur Heart J; 2014 Jul; 35(27):1792-800. PubMed ID: 24639426
[TBL] [Abstract][Full Text] [Related]
9. The influence of multiple oral administration on the pharmacokinetics and distribution profile of dalcetrapib in rats.
Takubo H; Ishikawa T; Taniguchi T; Iwanaga K; Nomura Y
Xenobiotica; 2021 Jan; 51(1):82-87. PubMed ID: 32783571
[TBL] [Abstract][Full Text] [Related]
10. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
11. Lowering LDL-C for optimal protection in high-risk patients.
Shaley FM
Am J Manag Care; 2008 Jan; 14(1):54; author reply 54-5. PubMed ID: 18197747
[No Abstract] [Full Text] [Related]
12. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Niesor EJ; Chaput E; Staempfli A; Blum D; Derks M; Kallend D
Atherosclerosis; 2011 Dec; 219(2):761-7. PubMed ID: 21982411
[TBL] [Abstract][Full Text] [Related]
13. [In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
Einecke D
MMW Fortschr Med; 2012 Apr; 154(7):28. PubMed ID: 22558865
[No Abstract] [Full Text] [Related]
14. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
15. Planning a clinical trial.
Brown WV; Bays HE; Maki KC; Wild RA
J Clin Lipidol; 2012; 6(6):484-95. PubMed ID: 23312046
[No Abstract] [Full Text] [Related]
16. Unrecognized confounders in overcoming clinical inertia study.
Federman DG
Am J Manag Care; 2008 Jan; 14(1):53-4; author reply 54-5. PubMed ID: 18197746
[No Abstract] [Full Text] [Related]
17. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Barter P; Rye KA
Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
[TBL] [Abstract][Full Text] [Related]
18. Prevention of atherosclerosis in coronary-artery bypass grafts.
Fuster V; Vorchheimer DA
N Engl J Med; 1997 Jan; 336(3):212-3. PubMed ID: 8988902
[No Abstract] [Full Text] [Related]
19. Atorvastatin improves myocardial perfusion in a patient with hypercholesterolemia and single-vessel coronary disease.
Feola M; Biggi A; Rolfo F; Papaleo A; Chauvie S; La Scala E; Uslenghi E
Clin Nucl Med; 2006 Mar; 31(3):166-7. PubMed ID: 16495741
[No Abstract] [Full Text] [Related]
20. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
Derks M; Abt M; Parr G; Meneses-Lorente G; Young AM; Phelan M
Expert Opin Investig Drugs; 2010 Oct; 19(10):1135-45. PubMed ID: 20738227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
